can glp 1 cause fainting GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment GLP-1 and Low Blood Pressure:

Upper arm injections generally require administration by another person

These injectable medications were originally designed for diabetes management, but clinical trials have demonstrated their effectiveness in addressing obesity and supporting significant weight loss

Important Note : If you have heart failure, chronic kidney disease, or liver disease, follow your healthcare provider's specific guidance on fluid intake, as these conditions may require fluid restriction rather than increased consumption

Notable findings include: In the SURMOUNT-1 trial of tirzepatide for the treatment of obesity, secondary findings showed improvements in the GLP-1 treatment group in systolic blood pressure (-7.2mm Hg), diastolic blood pressure (-4.8mm Hg), triglycerides (-24.8mg/dl), fasting insulin (-42.9mIU liter), and total cholesterol (-4.8mg/dl)

Disclosures: Alyssa Kriegermeier: Nothing to Disclose, Krupa Mysore: Nothing to Disclose, Estella Alonso: Nothing to Disclose, Aki Asai: Ipsen: Grant/Research Support, Mirum: Grant/Research Support, Moderna: Grant/Research Support, Ultragenyx: Grant/Research Support, Gilead: Grant/Research Support, Sanofi: Advisor, Kevin Bove: Nothing to Disclose, Laura Bull: Nothing to Disclose, Nathan Goodrich: Nothing to Disclose, Steve Guthery: Nothing to Disclose, Sanjiv Harpavat: Syneos Health: I sit on a Data Safety Monitoring Board, Simon Horslen: Nothing to Disclose, Evelyn Hsu: Albireo: Grant/Research Support, Mirum: Grant/Research Support, Gilead: Grant/Research Support, Karen Jones: Nothing to Disclose, Binita Kamath: Mirum: Consultant, Mirum: Grant/Research Support, Albireo/Ipsen: Consultant, Albireo/Ipsen: Grant/Research Support, Audentes: Consultant, Saul Karpen: Albireo/Ipsen: Consultant, Mirum: Consultant, HemoShear: Consultant, Intercept: Consultant, John Magee: Nothing to Disclose, Jean Molleston: Gillead: Grant/Research Support, Albireo: Grant/Research Support, Abbvie: Grant/Research Support, Mirum/Shire: Grant/Research Support, CF FOundation: Grant/Research Support, Alexander Miethke: Mirum Pharmaceutical Inc: Grant/Research Support, Mirum Pharmaceutical Inc: Consultant, Ipsen: Speaking and Teaching, Philip Rosenthal: Nothing to Disclose, Ronald Sokol: Nothing to Disclose, Kenneth Setchell: Nothing to Disclose, Benjamin Shneider: Nothing to Disclose, Richard Thompson: Generation Bio: Stock - publicly traded company, Generation Bio: Consultant, Rectify: Stock privately held company, Rectify: Consultant, Mirum: Consultant, Ipsen: Consultant, Alnylam: Consultant, Integra: Stock privately held company, Glycomine: Consultant, Spruce: Consultant, Pamela Valentino: Grifols: Advisor, Mirum: Speaking and Teaching, Wen Ye: Nothing to Disclose, Kathleen Loomes: Mirum: Consultant, Albireo/Ipsen: Consultant, Mirum: Clinical trials, Albireo/Ipsen: Clinical trials, Rohit Kohli: Mirum: Consultant, Ipsen: Consultant, Epigen: Grant/Research Support, Sanofi Rare Disease: Consultant 2485 ASSOCIATION OF ABNORMAL GLOBAL LONGITUDINAL STRAIN WITH WAITLIST DECOMPENSATION AND MORTALITY IN CHILDREN WITH BILIARY ATRESIA Manpreet Virk 1 Tam Doan 2 Erik Su 3 Sanjiv Harpavat 4 Nhu Thao Galvan 3 Hannah Todd 3 Lara Claudia 2 Anitha Parthiban 2 Moreshwar Desai 3 , 1 Baylor College of Medicine, Houston 77030, 2 Texas Children's Hospital, 3 Baylor College of Medicine, 4 Texas Children's Liver Center - Baylor College of Medicine Background: Cirrhotic cardiomyopathy (CCM) is prevalent in infants and children with biliary atresia (BA), and is associated with increased postoperative mortality and serious adverse events

Dose-response, safety and efficacy of oral semaglutide versus placebo and versus liraglutide, all as monotherapy in Japanese subjects with type 2 diabetes (PIONEER 9)